SCHEMBL839614

SCHEMBL839614

COC[C@@H](C)OCC(Oc1ncnc2c1cnn2-c1ncccc1Cl)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GCK P35557 19/20 0.65
KCNH2 Q12809 10/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839615 1.00 GCK (0.65) GCKKCNH2
SCHEMBL838954 0.93 GCK (0.67) GCKKCNH2
SCHEMBL838955 0.93 GCK (0.67) GCKKCNH2
SCHEMBL838953 0.93 GCK (0.67) GCKKCNH2
SCHEMBL839158 0.91 GCK (0.76) GCKKCNH2
SCHEMBL839329 0.89 GCK (0.60) GCKKCNH2
SCHEMBL839328 0.89 GCK (0.60) GCKKCNH2
SCHEMBL838076 0.88 GCK (0.63) GCKKCNH2
SCHEMBL838077 0.88 GCK (0.63) GCKKCNH2
SCHEMBL3125949 0.86 GCK (0.76) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 GCK 1/4885KCNH2 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.